Melissa Rewolinski
Director/Board Member at ARBUTUS BIOPHARMA CORPORATION
Net worth: 583 $ as of 30/05/2023
Profile
Melissa V.
Rewolinski is the founder of Mvr Consulting, Inc. (founded in 2018) where she holds the title of Principal.
She is currently the Director at American Type Culture Collection since 2021 and Independent Director at Arbutus Biopharma Corp.
since 2023.
Dr. Rewolinski previously served as an Independent Director at Lannett Co., Inc. from 2019 to 2023, Senior Director-Development at Amira Pharmaceuticals, Inc. from 2006 to 2008, and Senior Vice President & Head-Technical Operations at Intercept Pharmaceuticals, Inc. from 2008 to 2018.
She obtained her undergraduate and doctorate degrees from Rice University in 1991 and 1995, respectively.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
LANNETT COMPANY, INC.
0.22% | 30/10/2022 | 23,315 ( 0.22% ) | 583 $ | 30/05/2023 |
Melissa Rewolinski active positions
| Companies | Position | Start |
|---|---|---|
| ARBUTUS BIOPHARMA CORPORATION | Director/Board Member | 11/07/2023 |
| Mvr Consulting, Inc. | Founder | 31/07/2018 |
American Type Culture Collection
 American Type Culture Collection BiotechnologyHealth Technology American Type Culture Collection operates as a global biological materials resource and standards organization offering a collection of products and services. Its services include production and characterization, testing, biorepository, and deposit. The company was founded in 1925 and is headquartered in Manassas, VA. | Director/Board Member | 31/08/2021 |
Former positions of Melissa Rewolinski
| Companies | Position | End |
|---|---|---|
| LANNETT COMPANY, INC. | Director/Board Member | 15/06/2023 |
| INTERCEPT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 30/06/2018 |
Amira Pharmaceuticals, Inc.
 Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Corporate Officer/Principal | 31/03/2008 |
Training of Melissa Rewolinski
| Rice University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| LANNETT COMPANY, INC. | Health Technology |
| INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
| ARBUTUS BIOPHARMA CORPORATION | Health Technology |
| Private companies | 3 |
|---|---|
| Mvr Consulting, Inc. | |
Amira Pharmaceuticals, Inc.
Amira Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. The firm's team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and various fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease. | Health Technology |
American Type Culture Collection
American Type Culture Collection BiotechnologyHealth Technology American Type Culture Collection operates as a global biological materials resource and standards organization offering a collection of products and services. Its services include production and characterization, testing, biorepository, and deposit. The company was founded in 1925 and is headquartered in Manassas, VA. | Health Technology |
- Stock Market
- Insiders
- Melissa Rewolinski
